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Abstract: The purpose of this study was to use solid lipid nanoparticles (SLN) to improve 
the pharmacological activity of ofloxacin. Ofloxacin-loaded SLN were prepared using palmitic 
acid as lipid matrix and poly vinyl alcohol (PVA) as emulsifier by a hot homogenization 
and ultrasonication method. The physicochemical characteristics of SLN were investigated 
by optical microscope, scanning electron microscopy, and photon correlation spectroscopy. 
Pharmacokinetics was studied after oral administration in mice. In vitro antibacterial activity and 
in vivo antibacterial efficacy of the SLN were investigated using minimal inhibitory concentrations 
(MIC) and a mouse protection model. The results demonstrated that the encapsulation efficiency, 
loading capacity, diameter, polydispersivity index, and zeta potential of the nanoparticles were 
41.36% ± 1.50%, 4.40% ± 0.16%, 156.33 ± 7.51 nm, 0.26 ± 0.04, and −22.70 ± 1.40 mv, 
respectively. The SLN showed sustained release and enhanced antibacterial activity in vitro. 
Pharmacokinetic results demonstrated that SLN increased the bioavailability of ofloxacin by 
2.27-fold, and extended the mean residence time of the drug from 10.50 to 43.44 hours. Single 
oral administrations of ofloxacin-loaded nanoparticles at 3 drug doses, 5 mg/kg, 10 mg/kg, 
and 20 mg/kg, all produced higher survival rates of lethal infected mice compared with native 
ofloxacin. These results indicate that SLN might be a promising delivery system to enhance the 
pharmacological activity of ofloxacin.
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Introduction
Ofloxacin is one of the most widely available fluoroquinolone antibiotics. It has potent 
bactericidal activity against a broad range of clinically relevant Gram-negative and 
Gram-positive pathogens, as well as Mycoplasma, Chlamydia, and Legionella.1–4 This 
antibiotic has been effectively used to treat a variety of bacterial infections, including 
those of the respiratory tract, skin structure, bone, gastrointestinal tract, and urinary 
tract, and bacterial prostatitis, sexually transmitted diseases, and wound and surgical 
infections.1,3 Ofloxacin is normally administered orally.3
However, the poor aqueous solubility of ofloxacin gives rise to difficulties in 
the design of pharmaceutical formulations and leads to variable bioavailability.5,6 
In   addition, almost all of the oral ofloxacin formulations are available only as 
  conventional, immediate-release tablets that require twice daily administration 
for consecutive days or weeks.7–9 The repeated oral doses of ofloxacin over long time 
could result in nervous system and gastrointestinal system disorders.10,11 Efforts have 
been made to develop alternative formulations of ofloxacin to improve therapeutic 
efficacy and reduce frequency of administration.12–16 Ofloxacin-loaded liposomes International Journal of Nanomedicine 2011:6 submit your manuscript | www.dovepress.com
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produced higher intracellular drug concentrations and 
antimicrobial activities.15 The gastroretentive tablet and 
sustained-release pellet have been developed for once-daily 
administration.13,14
Solid lipid nanoparticles (SLN) have attracted increasing 
attention in pharmaceutics as an alternative dosage form to 
liposomes and polymeric nanoparticles. SLN possess good 
tolerability and stability, scaling-up feasibility, and the ability 
to incorporate hydrophobic/hydrophilic drugs.17–19 The 
incorporation of poorly soluble drugs into SLN can enhance 
gastrointestinal solubilization, absorption, and bioavailability 
of drug.20,21 Pandey et al demonstrated that 5 oral doses of 
antitubercular drug-loaded SLN administered every 10 days 
provided an equivalent therapeutic benefit to 46 daily doses 
of oral free drugs.22 Our research showed that SLN could 
significantly extend systemic circulation times, enhance 
antibacterial activity in vitro, increase the bioavailability, 
reduce the dose and frequency of administration, and 
decrease side effects of tilmicosinin.23,24 Fatty acid-SLN 
increased the bioavailability and extended the mean residence 
time of enrofloxacin by several-fold.25
In this study, ofloxacin-loaded palmitic acid SLN was 
prepared using palmitic acid as lipid matrix and poly vinyl 
alcohol (PVA) as emulsifier by a hot homogenization and 
ultrasonication method. The palmitic acid has been adopted 
to prepare SLN. PVA is the most commonly used emulsifier 
in the formulation of nanoparticles due to its excellent 
mechanical strength, biocompatibility and nontoxicity, and 
has been approved by the US Food and Drug Administration 
for medical and food applications.26 The hot homogenization 
and ultrasonication method was feasible to prepare poor 
water solubility drug-loaded SLN.24,25,27 The physicochemical 
properties and pharmacokinetics of the SLN were investigated 
and the antibacterial activities of ofloxacin-loaded SLN against 
Staphylococcus aureus were evaluated in vitro and in vivo.
Materials and methods
Materials
Palmitic  acid  was  bought  from  Shanghai  Sangon 
Biological Engineering Technology & Services Co., Ltd. 
(Shanghai, China). Ofloxacin was obtained from Wuhan 
Konglong Century Technology Development Co., Ltd. 
(Wuhan, China). PVA was purchased from Sigma-Aldrich 
(St. Louis, MO, USA). Ofloxacin reference standard 
was available from China Institute of Veterinary Drug 
Control (Beijing, China). Methyl alcohol used for high 
performance liquid chromatography (HPLC) was of liquid 
chromatography (LC) grade and was purchased from Tedia 
Company, Inc (USA). The water for HPLC was prepared 
with a Milli-Q system (Millipore, Bedford, MA). Citric acid 
was obtained from Sinopharm Chemical Reagent Co., Ltd. 
(Beijing, China). Other chemicals and reagents not specified 
in the text were of analytical grade or equivalent.
Animals and bacteria
Kunming species mice (male, 30 ± 1 g) were obtained from 
the Medical Animal Test Center of Peking University, China. 
The animals were housed at room temperature under natural 
day and night cycles with free access to water and normal 
mice food (Beijing Keao Xieli Co., Ltd., China). They were 
kept for at least 1 week before use. After experiments, all 
the surviving mice were sacrificed by cervical dislocation. 
All experimental protocols concerning the handling of mice 
were in accordance with the requirements of the Institutional 
Animal Care and Use Committee at China Agricultural 
University.
S. aureus (CCVCC2248) was available from China 
Institute of Veterinary Drug Control (Beijing, China). 
Bacteria were streaked from glycerol-frozen stocks onto 
agar plates and incubated overnight at 37°C. A single 
bacterial colony from the fresh plates was inoculated in the 
Mueller–Hinton broth (MH) and grown at 37°C in a shaking 
incubator at 230 rpm to an OD600 of 0.6, which corresponds to 
∼8 × 108 colony forming units (cfu)/mL, confirmed by plating 
serial dilutions. For in vitro study, the bacteria were diluted 
in broth. For in vivo study, the bacteria were collected by 
centrifugation at 4000 rpm (Centrifuge 5810 R; Eppendorf, 
Germany) for 10 minutes at 4°C and resuspended in sterile 
saline at different concentrations.
Preparation of ofloxacin-loaded SLN
Nanoparticles were prepared by a hot homogenization and 
ultrasonication method. Palmitic acid (4.5 g) and ofloxacin 
(0.5 g) were added in a 100 mL beaker and heated to 150°C 
by a homeothermia magnetic stirrer (Shanghai Zhenrong 
Scientific Instrument Co., Ltd., China). After the drug 
was dissolved in the melted palmitic acid, the oil phase 
was poured into 120 mL of boiling 1% PVA solution 
under magnetic stirring at 150 rpm for 3 minutes to form 
an oil in water emulsion, and then further sonicated for 
5 minutes (VC × 750 Vibra-CellTM, Sonics and Materials, 
Inc., Newtown, CT, USA, using the 13 mm microprobe 
with amplitude 35%) to form a nanoemulsion. The hot 
nanoemulsion was quickly poured into 400 mL cold water 
to obtain a nanoparticle suspension. The nanoparticles were 
collected by centrifugation at 12000 rpm (Centrifuge 5810 R; International Journal of Nanomedicine 2011:6 submit your manuscript | www.dovepress.com
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Eppendorf, Germany) for 60 minutes at 4°C, and washed 
3 times with distilled water. The SLN were re-suspended 
in 120 mL distilled water and lyophilized for 48 hours 
(LGJ-12 Freeze Dryer; Beijing Songyuanhuaxing Science 
Technology Development Co., Ltd., China). The control SLN 
was prepared similarly without adding ofloxacin.
Microscopic analysis
Briefly, 5 mg freeze-dried SLN was suspended in 1 mL 
double distilled water and two micro liters of the suspension 
were placed on a microscope slide surface. Photomicrographs 
of the SLN were taken using an inverted optical microscope 
(Olympus 1X71, Olympus, Japan).
scanning electron microscopy (seM)  
of nanoparticles
The morphology of nanoparticles was investigated by SEM 
(SE S-3400N; HITACHI, Japan). Briefly, 10 mg freeze-dried 
SLN was suspended in 1 mL distilled water and 2 µL of the 
suspension was placed on a glass surface. After oven-drying, 
the samples were coated with gold using an Ion Sputter and 
examined at an accelerating voltage of 20 kV .
Determination of loading capacity  
and encapsulation efficiency
To determine SLN incorporation capacity, 10 mg freeze-
dried SLN was dissolved in chloroform and the solution was 
analyzed directly at 287.8 nm using a UV spectrophotometer 
(U-1800, Hitachi Tech Co., Ltd., Japan). The control SLN 
prepared without drug were treated similarly and used as 
control for the measurements. The assay was repeated three 
times using different samples from independent preparations. 
Loading capacity (LC) and encapsulation efficiency (EE) are 
defined as follows:27
LC = [(weight of ofloxacin in SLN)/
(weight of SLN)] × 100%
EE = [(weight of ofloxacin in SLN)/
(weight of ofloxacin added)] × 100%
Determination of particle size, 
polydispersity index, and zeta potential
The size, polydispersity index (PDI), and zeta potential of 
ofloxacin-loaded SLN were measured by photon correlation 
spectroscopy (PCS) using Zetasizer Nano ZS90 (Malvern 
Instruments, UK) at 25°C. The samples were suspended in 
distilled water by ultrasonication for 5 seconds at 0°C to remove 
air bubbles and break up agglomerates. The concentration of 
sample was 2.7 mg/mL for particle size and PDI, 0.3 mg/mL 
for zeta potential determinations to get optimum kilo counts 
per second (kcps) of 20 to 400 for measurements.
Determination of residual PVA
The amount of PVA associated with ofloxacin-loaded 
SLN was determined by a colorimetric method described 
previously.27 Briefly, 8 mg lyophilized SLN was treated with 
2 mL 0.5 M NaOH for 15 minutes at 60°C. Each sample was 
neutralized with 900 µl 1 M HCl and the volume was adjusted 
to 5 mL with distilled water. The solution was filtered with 
0.22 µm filters and mixed with 3 mL 0.65 M boric acid 
solution, 0.5 mL I2/KI (0.05 M/0.15 M) solution and 1.5 mL 
distilled water. Following incubation at room temperature for 
15 minutes, the absorbance was measured at 690 nm using a 
UV spectrophotometer (U-1800, Hitachi, Japan). A standard 
plot of PVA was done under identical conditions.
In vitro release studies
Ofloxacin-loaded SLN (10 mg) or native ofloxacin 
(400 µg) were suspended or dissolved in 2 mL 0.1 M sterile 
  hydrochloric acid (donor solution) in a dialysis bag and 
  dialyzed against 45 mL 0.1 M sterile hydrochloric acid 
(receiver solution) in a 50 mL tube at 37°C under magnetic 
stirring at 100 rpm. To determine the ofloxacin amount 
  diffused through the   dialysis bag, samples (2 mL) were 
taken from the receiver   solution and the same amount of 
fresh 0.1 M sterile   hydrochloric acid was added to keep a 
constant volume at fixed time points. The sink conditions 
were maintained for release study. Ofloxacin in the samples 
was measured   spectrophotometrically at 287.8 nm using a 
UV   spectrophotometer (U-1800, Hitachi Tech Co., Ltd., 
Japan). The control nanoparticles without ofloxacin were 
treated similarly and used as blanks for the measurements.
Antibacterial activity studies
Minimal inhibitory concentrations (MIC) were determined 
by the Clinical and Laboratory Standards Institute (CLSI) 
micro-dilution method.28 S. aureus (100 µL, concentration 
∼1 × 106 cfu/mL) was added to each well of a 96-well plate 
containing 100 µL of ofloxacin-loaded SLN suspension in 
MH. The final bacterium concentration in individual wells 
was ∼5 × 105 cfu/mL. The final ofloxacin concentrations 
were 0.05, 0.1, 0.2, 0.3, 0.4, 0.5, 0.6, 0.7, and 0.8 µg/mL. 
The plate was incubated at 37°C and the MIC was determined 
as the lowest concentration with clear wells at 12, 24, 36, 
and 48 hours. The MIC of native and released ofloxacin was 
measured in the same way.International Journal of Nanomedicine 2011:6 submit your manuscript | www.dovepress.com
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Pharmacokinetics study
Before initiation of the experiment, 50 mice were randomly 
divided into 10 groups with 5 animals in each group. Then 
0.3 mg naked ofloxacin dissolved in 200 µL sterile distilled 
water or 6.8 mg ofloxacin-SLN containing 0.3 mg ofloxacin 
suspended in 200 µL sterile distilled water was administered 
orally to each mouse. At different time points (0.08, 0.17, 
0.33, 0.5, 1, 2, 4, 8, 12, 18, 24, 36, 48, 72, 96, 120 hours) 
post-administration, blood samples were taken from the tail 
vein and the drug levels in the plasma were assayed. For each 
treatment, 5 groups of mice were contained and the blood 
samples (500 µL) were collected in turn from 5 groups over 
the observation period because of the limited blood volume 
that could be safely collected from each mouse.
hPLc assay
Ofloxacin concentrations in plasma were determined by 
HPLC. The method consists of reverse-phase chromatography 
and fluorimetric detection. Chromatographic conditions 
were as follows: excitation wavelength, 360; emission 
wavelength, 465; column, VP-ODS 250 mm × 4.6 mm 
(Shimadzu Coperation, Kyoto, Japan); mobile phase, 
0.05 mol/L citric acid (pH of the aqueous phase was 
adjusted by triethylamine to 3.5)/acetonitrile (85/15, 
v/v); flow rate, 1 mL/min; column temperature, 25°C. 
Sample extracts were prepared by mixing 100 µL plasma 
with 200 µL mixture of methyl alcohol and acetonitrile 
(1/1 v/v). The mixtures were vortexed for 3 minutes 
to allow complete mixing, followed by centrifugation 
at 14000 rpm (Sigma 1-14; Sartorius, Germany) for 
25 minutes. Then 50 µL supernatant was used for HPLC 
analysis. The plasma concentration of ofloxacin was 
found to be linear over the range 0.06 to 4 µg/mL. The 
correlation coefficient was 0.9996. The lowest value of 
the standard curve (0.056 µg/mL) was taken as the limit 
of quantitation. The recovery for the plasma ofloxacin from 
3 concentrations (0.1, 1, and 4 µg/mL) was 80.13% ± 5.14%, 
87.37% ± 3.51%, and 89.25% ± 2.19%, respectively. The 
relative standard deviations (RSD) of accuracy and 
precision for 3 different plasma concentrations of ofloxacin 
(0.1, 1, and 4 µg/mL) were 5.38%, 2.99%, and 1.86% for 
intra-day analysis, and 4.58%, 3.03%, and 1.40% for inter-
day analysis, respectively.
Pharmacokinetic analysis
The data of plasma ofloxacin concentration-time were 
analyzed based on noncompartmental pharmacokinetics 
using the PK Solutions 2.0 (Ashland, OH, USA) computer 
software.
In vivo efficacy studies
Determination of the minimum lethal dose: bacteria (0.3 mL 
at concentrations of 3 × 109, 6 × 109, and 12 × 109 cfu/mL) 
were injected intraperitoneally into each mouse of 3 groups 
with 10 mice in each group. Mice deaths were observed every 
12 hours over a 72-hour period to determine the inoculum 
size of lethal infection.
Drug treatment and efficacy evaluation: 70 mice were 
randomly divided into 7 groups with 10 animals in each 
group. Each mouse was injected intraperitoneally with the 
minimum lethal infection inoculum size of bacteria. Infected 
mice were orally administrated with a single dose of ofloxacin-
loaded SLN (suspended in 200 µL sterile distilled water) or 
native ofloxacin (dissolved in 200 µL sterile distilled water) 
2 hours post-infection. The dose of ofloxacin was 5 mg/kg, 
10 mg/kg, and 20 mg/kg, respectively. A separate group of 
control animals was administrated orally with 200 µL sterile 
water. Animals were observed every 12 hours and deaths 
were recorded over a 120-hour period.
statistical methods
The data on loading capacity, encapsulation efficiency, particle 
size, and PDI, as well as zeta potential and pharmacokinetic 
parameters  were  analyzed  using  one-way ANOVA. 
Significance was evaluated at a P value of 0.05. Statistical 
analysis was performed using Microsoft Excel (2003).
Results
Physicochemical characteristics of sLN
Photographs showed that SLN were spherical (Figure 1B), 
well dispersed with good particle size distributions 
(Figure 1A). Further PCS analysis demonstrated that the 
B A
Figure  1  Photographs  of  ofloxacin-loaded  solid  lipid  nanoparticles:  A)  optical 
microscope (magnification ×400); B) scanning electron microscope.International Journal of Nanomedicine 2011:6 submit your manuscript | www.dovepress.com
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mean particle size of SLN was 156.33 ± 7.51 nm with 
PDI 0.26 ± 0.04 and zeta potential −22.70 ± 1.40 mV . The 
loading capacity and encapsulation efficiency of SLN were 
4.40% ± 0.16% and 41.36% ± 1.50%. The residual PVA 
associated with the SLN was 1.28% ± 0.12% (Table 1).
In vitro release
In vitro release curve of ofloxacin-SLN exhibited a biphasic 
pattern (Figure 2). There was a fast phase with about 34.33% 
drug released within the initial 24 hours, followed by a slow 
and sustained phase. The amount of cumulated drug over 
120 hours was 49.15%. In the ofloxacin solution control, 
the release was about 92.45% within 2 hours and reached 
100% by 24 hours.
In vitro antibacterial activity
In vitro antibacterial activity studies showed that the MIC of 
the native ofloxacin increased with the increase of incubation 
time. The released ofloxacin had the same MIC as the native 
ofloxacin at all time points. At 12 hours ofloxacin-SLN had 
the same MIC as native ofloxacin, but later ofloxacin-SLN 
had a lower MIC than native ofloxacin (Table 2).
Pharmacokinetics
After oral administration of ofloxacin solution, plasma drug 
concentration reached a peak level of 1.2 µg/mL at 0.60 hours, 
then slowly decreased (Figure 3). The plasma drug level 
dropped to 0.08 µg/mL by 12 hours and was undetectable 
by 18 hours. In the SLN groups, ofloxacin reached a 
significantly higher peak concentration of 3.64 µg/mL at 
0.33 hours, then decreased sharply to the same levels of native 
drug 1 hour post-administration. Although the plasma drug 
concentration similarly decreased to 0.09 µg/mL at 12 hours, 
the concentration was maintained over 0.08 µg/mL for up to 
48 hours in the nanoparticles groups.
The AUC0–∞ value of ofloxacin-loaded SLN was 2.27-fold 
higher than those obtained with the ofloxacin solution 
(Table 3). The elimination half-life (T1/2el) and the mean 
residence time (MRT) were also enhanced significantly 
compared with the ofloxacin solution.
In vivo antibacterial efficacy
The mortality rates of mice infected with the 3   inoculations 
(3 × 109, 6 × 109, and 12 × 109 cfu) were 60%, 100%, 
and 100%, respectively (Figure 4). The inoculation of 
6 × 109 cfu/mL was selected as the minimum lethal inocula-
tion size and used for the subsequent treatment studies.
Figure 5 shows the survival rates of infected mice 
treated with ofloxacin-loaded SLN and ofloxacin solution. 
The survival curves show that SLN is superior to ofloxacin 
solution. The proportion of survivors for 5 mg/kg, 10 mg/kg, 
and 20 mg/kg doses in ofloxacin-loaded SLN groups were 
3/10 (30%), 5/10 (50%), and 6/10 (60%) over the observed 
period, respectively, compared with 0/10 (0%), 3/10 (30%), 
and 3/10 (30%) in ofloxacin solution groups.
Discussion
In this study, ofloxacin-loaded SLN were prepared by a hot 
homogenization and ultrasonication method. In this method, 
the choice of lipid is crucial in the formulation design.29 Lipids 
must be selected based on their ability to solubilize the drug.29 
Table 1 Physicochemical characteristics of ofloxacin-loaded solid lipid nanoparticles (mean ± sD, n = 3)
EE (%) LC (%) MD (nm) PDI ZP (mv) RP (%)
41.36 ± 1.50 4.40 ± 0.16 156.33 ± 7.51 0.26 ± 0.04 −22.70 ± 1.40 1.28 ± 0.12
Abbreviations: EE, encapsulation efficiency; LC, loading capacity; MD, mean diameter; PDI, polydispersity index; ZP, zeta potential; RP, residual PVA.
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Figure 2 In vitro release of native ofloxacin solution and ofloxacin-loaded solid lipid 
nanoparticles (sLN) (mean ± sD, n = 3).
Table 2 Minimal inhibitory concentrations (MIC) of ofloxacin 
(n = 3)
Ofloxacin MIC (μg/mL)
12 h 24 h 36 h 48 h
Native  0.2 0.4 0.5 0.5
released 0.2 0.4 0.5 0.5
SLN-loaded 0.2 0.3 0.3 0.3
Abbreviation: sLN, solid lipid nanoparticles.International Journal of Nanomedicine 2011:6 submit your manuscript | www.dovepress.com
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Palmitic acid was selected because of its high dissolution of 
ofloxacin, although other lipids such as hydrogenated castor 
oil had better characteristics used as lipid matrices to prepare 
SLN.23,27 Hydrogenated castor oil-SLN was an effective 
nanoparticle system for controlled release and enhancement 
of pharmacological activities of encapsulated drugs,23,27 but 
ofloxacin hardly dissolved in the melted lipid.
Ofloxacin had good retention in the drug–lipid mixture 
once it was dissolved. The drug did not crystallize from 
the melted palmitic acid even when the temperature of 
the mixture decreased from 150°C to 85°C. Therefore, the 
ofloxacin could stay dispersed in the melted lipid during the 
emulsification process, and the status was maintained during 
the fast cooling of the emulsion. Part of the drug diffused 
into the PVA solution, resulting in lower drug encapsulation 
efficiency and loading capacity.19 In addition, the drug 
maintained its stability and antibacterial activity because the 
temperature in the preparation did not exceed the melting 
point of ofloxacin (270 to 275°C). The preparation resulted 
in consistent nanoparticles of 156.33 ± 7.51 nm with narrow 
size distribution. The small size of nanoparticles is favorable 
for improving the per oral performance of incorporated 
poorly soluble drugs.30
The initial fast release of the drug could be due to 
desorption and diffusion of ofloxacin accumulated at the oil–
water interface and in the outer shell of nanoparticles.17,19,23,24 
The initial release should be sufficiently rapid to ensure that 
the therapeutic drug levels are achieved in a timely manner 
in vivo. The subsequent slow release is mainly due to the 
slow diffusion of drug molecules through the lipid matrix 
of the nanoparticles.17–19 Slow drug release will contribute to 
maintaining the effective therapeutic drug concentrations.
In vitro antibacterial activity studies showed that the MIC 
of native ofloxacin increased with the increase of incubation 
time. This could be explained by the fact that the native drug 
gradually loses its effect and bacteria that escaped drug 
action can multiply rapidly.31 SLN enhanced the antibacterial 
efficacy of ofloxacin against S. aureus evaluated by MIC, 
possibly because of better penetration of nanoparticles into 
the bacterial cells and better delivery of drug to its site of 
action.30,32 Sustained release of nanoparticles could also 
enhance the antibacterial efficacy of antibiotics.24,31
SLN significantly increased the bioavailability and 
extended the systemic circulation of ofloxacin. This could 
be attributed to a number of reasons. Because of their 
large surface area, SLN could improve the dissolution 
rate and level of drug in the presence of gastrointestinal 
fluids,29,30 leading to shorter Tmax and higher peak plasma 
ofloxacin concentration. In addition, SLN may adhere to 
the gastrointestinal tract wall or enter the intervillar spaces 
because of their small particle size, thus increasing their 
residence time in the gastrointestinal tract.33,34 Moreover, 
nanoparticles could protect the drug from chemical and 
enzymatic degradation and gradually release drug from the 
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Figure 3 Plasma ofloxacin concentration–time curves after oral administration of ofloxacin-loaded solid lipid nanoparticles (SLN) and ofloxacin solution in mice (mean ± sD, 
n = 5). A) within 8 hours; B) from 8 to 72 hours.
Table 3 Pharmacokinetic parameters of ofloxacin after oral administration in mice (mean ± sD, n = 5)
Formulation MRT (h) AUC0–∞ (mg/h/L) Cmax (μg/mL) Tmax (h) T1/2ab (h) T1/2el (h)
sLN 43.44 ± 13.36a 12.24 ± 1.50a 3.64 ± 0.48a 0.33a  0.06 ± 0.03a 28.72 ± 9.66a 
solution 10.50 ± 2.81   5.39 ± 0.45 1.12 ± 0.12 0.60 ± 0.22 0.17 ± 0.05   9.10 ± 1.63
Notes: aStatistical significance compared with solution, P , 0.05.
Abbreviations: MrT, mean residence time; AUc0–∞, area under the concentration–time curve from zero to infinity; Cmax, maximal ofloxacin concentration in plasma; 
Tmax, time to reach cmax; T1/2ab, absorption half-life; T1/2el, elimination half-life.International Journal of Nanomedicine 2011:6 submit your manuscript | www.dovepress.com
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lipid matrix into blood,27 resulting in a several-fold increase 
in MRT compared with native drug.
Although the sustained-release performance of the 
ofloxacin-loaded SLN was not as good as that of the other drug-
loaded SLN in our previous studies,23,25,27 the concentration of 
0.09 µg/mL was therapeutically effective for many common 
pathogens.2,4,9,35
The determination of survivorship in an experimental 
mouse infection model remains a primary model for 
evaluation of efficacy of antimicrobial agents.36 The 
higher proportions of survivors indicate that SLN 
enhanced the in vivo antimicrobial efficacy of ofloxacin. 
Previous research suggests that the therapeutic activities 
of fluoroquinolones in experimental infections are related 
to their pharmacokinetic behavior.37,38 Ofloxacin exhibits 
concentration-dependent antibacterial activity.39 The higher 
AUC and peak plasma concentrations (Cmax) can improve 
its bactericidal efficacy. The sustained release could result 
in better in vivo efficacy. Although the sustained plasma 
concentration was lower than the MIC of ofloxacin against 
S. aureus, ofloxacin penetrates efficiently throughout 
the body, with concentrations in tissues and body fluids 
reported to be higher than those in plasma.2,3,9,40 Besides, the 
long post-antibiotic effect of ofloxacin can prevent bacteria 
regrowth even when plasma and tissue concentrations 
decrease below MIC.39,41 The interaction of SLN with 
bacteria might also enhance the in vivo bactericidal 
efficiency of ofloxacin, but further experiments need to be 
done to elucidate this effect.
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Figure 4 Percentage survival of mice infected with different inoculations of S. aureus 
(ccVcc2248). Inoculations: low dose: 3 × 109 cfu/mL; medium dose: 6 × 109 cfu/mL; 
high dose: 12 × 109 cfu/mL.
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Conclusion
Ofloxacin was successfully incorporated into palmitic acid-
SLN by a hot homogenization and ultrasonication method. 
SLN had a sustained-release effect and enhanced antibacterial 
activity against S. aureus in vitro. SLN significantly improved 
the bioavailability, systematic circulation time, and in vivo 
efficacy of ofloxacin. The nanoparticle system would be an 
effective vehicle for oral delivery of ofloxacin to improve 
its pharmacological activity.
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